Related Experiment Video

Updated: Jul 27, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

INHIBITION OF LANDSCHUETZ ASCITES TUMOUR GROWTH BY METAL CHELATES DERIVED FROM

F P DWYER, E MAYHEW, E M ROE

    British Journal of Cancer
    |March 1, 1965
    PubMed
    Abstract

    No abstract available in PubMed .

    Keywords:
    ANTINEOPLASTIC AGENTSCOPPEREXPERIMENTAL LAB STUDYMICENEOPLASMS, EXPERIMENTALPHARMACOLOGYPHENANTHROLINESRUTHENIUM

    More Related Videos

    An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles09:00

    An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

    Published on: March 18, 2015

    Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides11:04

    Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

    Published on: September 7, 2019

    Related Concept Videos

    Extraction: Advanced Methods00:56

    Extraction: Advanced Methods

    Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is formed in...
    Antiprotozoal Agents01:21

    Antiprotozoal Agents

    Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...